Development of Latent Cytokine Fusion Proteins

Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Volumn , Issue , 2013, Pages 237-252

  Mullen, Lisa ^a   Adams, Gill ^a   Fatah, Rewas ^a   Gould, David ^a   Rigby, Anne ^a   Sclanders, Michelle ^a   Koutsokeras, Apostolos ^a   Mittal, Gayatri ^a   Vessillier, Sandrine ^a   Chernajovsky, Yuti ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Alternatives variants; Cytokine generation; Cytokine, limitations; Latent cytokine FPs; Multiple sclerosis

Indexed keywords

EID: 84886137202     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118354599.ch16     Document Type: Chapter

References (107)

1. Oppenheim JJ. (2001) Cytokines: past, present, and future. Int. J. Hematol. 74, 3-8.
2. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. (1988) Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin. Exp. Immunol. 73, 449-455.
3. Wood NC, Symons JA, Dickens E, Duff GW. (1992) In situ hybridization of IL-6 in rheumatoid arthritis. Clin. Exp. Immunol. 87, 183-189.
4. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. (1997) Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat. Med. 3, 189-195.
5. Tayal V, Kalra BS. (2008) Cytokines and anti-cytokines as therapeutics-an update. Eur. J. Pharmacol. 579, 1-12.
6. Vilcek J, Feldmann M. (2004) Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol. Sci. 25, 201-209.
7. Adams G, Vessillier S, Dreja H, Chernajovsky Y. (2003) Targeting cytokines to inflammation sites. Nat. Biotechnol. 21, 1314-1320.
8. Nissim A, Gofur Y, Vessillier S, Adams G, Chernajovsky Y. (2004) Methods for targeting biologicals to specific disease sites. Trends Mol. Med. 10, 269-274.
9. Brinckerhoff CE, Matrisian LM. (2002) Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 3, 207-214.
10. Burrage PS, Brinckerhoff CE. (2007) Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr. Drug Targets 8, 293-303.
11. Burrage PS, Mix KS, Brinckerhoff CE. (2006) Matrix metalloproteinases: role in arthritis. Front Biosci. 11, 529-543.
12. Visse R, Nagase H. (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827-839.
13. Nagase H, Visse R, Murphy G. (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562-573.
14. Nagase H, Woessner JF, Jr. (1999) Matrix metalloproteinases. J. Biol. Chem. 274, 21491-21494.
15. Mandal M, Mandal A, Das S, Chakraborti T, Sajal C. (2003) Clinical implications of matrix metalloproteinases. Mol. Cell Biochem. 252, 305-329.
16. Sporn MB, Harris ED, Jr. (1981) Proliferative diseases. Am. J. Med. 70, 1231-1235.
17. Rosenberg GA. (1995) Matrix metalloproteinases in brain injury. J. Neurotrauma 12, 833-842.
18. Rosenberg GA. (2002) Matrix metalloproteinases in neuroinflammation. Glia 39, 279-291.
19. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al. (1995) Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92, 1565-1569.
20. Galis ZS, Khatri JJ. (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90, 251-262.
21. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. (1999) Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum. 42, 90-99.
22. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, et al. (2001) Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferonbeta-1a with preserved in vitro bioactivity. J. Pharmacol. Exp. Ther. 297, 1059-1066.
23. Gould DJ, Bright C, Chernajovsky Y. (2004) Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmid. Arthritis Res. Ther. 6, R103-113.
24. Xiong ZF, Hu S, Wang ZH. (2010) Role of a latent soluble TNF receptor type I (hsTNFRI) fusion protein in targeted treatment of endometriosis. Zhonghua Yi Xue Za Zhi 90, 768-771.
25. Spuijbroek MD, Dunselman GA, Menheere PP, Evers JL. (1992) Early endometriosis invades the extracellular matrix. Fertil. Steril. 58, 929-933.
26. Sillem M, Prifti S, Koch A, Neher M, Jauckus J, Runnebaum B. (2001) Regulation of matrix metalloproteinases and their inhibitors in uterine endometrial cells of patients with and without endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 95, 167-174.
27. Neve R, Kissonerghis M, Clark J, Feldmann M, Chernajovsky Y. (1996) Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist. Cytokine 8, 365-370.
28. Moren A, Olofsson A, Stenman G, Sahlin P, Kanzaki T, Claesson-Welsh L, et al. (1994) Identification and characterization of LTBP-2, a novel latent transforming growth factor-beta-binding protein. J. Biol. Chem. 269, 32469-32478.
29. Olofsson A, Ichijo H, Moren A, ten Dijke P, Miyazono K, Heldin CH. (1995) Efficient association of an amino-terminally extended form of human latent transforming growth factor-beta binding protein with the extracellular matrix. J. Biol. Chem. 270, 31294-31297.
30. Saharinen J, Keski-Oja J. (2000) Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol. Biol. Cell 11, 2691-2704.
31. Wakefield LM, Smith DM, Broz S, Jackson M, Levinson AD, Sporn MB. (1989) Recombinant TGF-beta 1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-beta 1 complex. Growth Factors 1, 203-218.
32. Brunner AM, Marquardt H, Malacko AR, Lioubin MN, Purchio AF. (1989) Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J. Biol. Chem. 264, 13660-13664.
33. Leavitt R, Schlesinger S, Kornfeld S. (1977) Impaired intracellular migration and altered solubility of nonglycosylated glycoproteins of vesicular stomatitis virus and Sindbis virus. J. Biol. Chem. 252, 9018-9023.
34. Machamer CE, Rose JK. (1988) Influence of new glycosylation sites on expression of the vesicular stomatitis virus G protein at the plasma membrane. J. Biol. Chem. 263, 5948-5954.
35. Dorner AJ, Bole DG, Kaufman RJ. (1987) The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J. Cell Biol. 105, 2665-2674.
36. Sha X, Brunner AM, Purchio AF, Gentry LE. (1989) Transforming growth factor beta 1: importance of glycosylation and acidic proteases for processing and secretion. Mol. Endocrinol. 3, 1090-1098.
37. Lopez AR, Cook J, Deininger PL, Derynck R. (1992) Dominant negative mutants of transforming growth factor-beta 1 inhibit the secretion of different transforming growth factorbeta isoforms. Mol. Cell Biol. 12, 1674-1679.
38. Brunner AM, Lioubin MN, Marquardt H, Malacko AR, Wang WC, Shapiro RA, et al. (1992) Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta 1 (TGF beta 1) and TGF beta 2 (414) precursors and of cysteine residues within mature TGF beta 1: effects on secretion and bioactivity. Mol. Endocrinol. 6, 1691-1700.
39. Sinclair AM, Elliott S. (2005) Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94, 1626-1635.
40. Werner RG, Kopp K, Schlueter M. (2007) Glycosylation of therapeutic proteins in different production systems. Acta Paediatr. Suppl. 96, 17-22.
41. Brunner AM, Gentry LE, Cooper JA, Purchio AF. (1988) Recombinant type 1 transforming growth factor beta precursor produced in Chinese hamster ovary cells is glycosylated and phosphorylated. Mol. Cell Biol. 8, 2229-2232.
42. Purchio AF, Cooper JA, Brunner AM, Lioubin MN, Gentry LE, Kovacina KS. (1988) Identification of mannose 6-phosphate in two asparagine-linked sugar chains of recombinant transforming growth factor-beta 1 precursor. J. Biol. Chem. 263, 14211-14215.
43. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. (1990) Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J. Clin. Invest. 86, 1976-1984.
44. Miyazono K, Heldin CH. (1989) Role for carbohydrate structures in TGF-beta 1 latency. Nature 338, 158-160.
45. Yang Y, Dignam JD, Gentry LE. (1997) Role of carbohydrate structures in the binding of beta1-latency-associated peptide to ligands. Biochemistry 36, 11923-11932.
46. Chitlaru T, Kronman C, Zeevi M, Kam M, Harel A, Ordentlich A, et al. (1998) Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. Biochem. J. 336, 647-658.
47. Poser CM, Brinar VV. (2004) The nature of multiple sclerosis. Clin. Neurol. Neurosurg. 106, 159-171.
48. Arnason BG. (1999) Immunologic therapy of multiple sclerosis. Annu. Rev. Med. 50, 291-302.
49. Hohlfeld R, Wekerle H. (2001) Immunological update on multiple sclerosis. Curr. Opin. Neurol. 14, 299-304.
50. Rott O, Fleischer B, Cash E. (1994) Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24, 1434-1440.
51. Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK. (1998) IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10-and IL-4-deficient and transgenic mice. J. Immunol. 161, 3299-3306.
52. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. (1998) IL-10 reduces rat brain injury following focal stroke. Neurosci. Lett. 251, 189-192.
53. Plunkett JA, Yu CG, Easton JM, Bethea JR, Yezierski RP. (2001) Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. Exp. Neurol. 168, 144-154.
54. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M. (2004) Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab. Brain Dis. 19, 195-206.
55. Juul S. (2004) Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin. Perinatol. 31, 129-142.
56. Brines M, Cerami A. (2005) Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 6, 484-494.
57. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, et al. (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 952, 128-134.
58. Li W, Maeda Y, Yuan RR, Elkabes S, Cook S, Dowling P. (2004) Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann. Neurol. 56, 767-777.
59. Zhang J, Li Y, Cui Y, Chen J, Lu M, Elias SB, et al. (2005) Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. 1034, 34-39.
60. Rosenberg GA. (2002) Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 8, 586-595.
61. Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, et al. (2006) Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin. Neurol. Neurosurg. 108, 124-128.
62. YongVW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM. (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J. Neurol. Sci. 259, 79-84.
63. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, et al. (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130, 2577-2588.
64. Schluesener HJ, Lider O. (1989) Transforming growth factors beta 1 and beta 2: cytokines with identical immunosuppressive effects and a potential role in the regulation of autoimmune T cell function. J. Neuroimmunol. 24, 249-258.
65. Johns LD, Flanders KC, Ranges GE, Sriram S. (1991) Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J. Immunol. 147, 1792-1796.
66. McCartney-Francis NL, Frazier-Jessen M, Wahl SM. (1998) TGF-beta: a balancing act. Int. Rev. Immunol. 16, 553-580.
67. van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ. (2004) Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Ther. 6, R239-249.
68. Schuppan D, Freitag T. (2004) Fistulising Crohn's disease: MMPs gone awry. Gut 53, 622-624.
69. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. (2000) Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47, 63-73.
70. Shah PK, Galis ZS. (2001) Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation 104, 1878-1880.
71. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA, et al. (1999) Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 19, 2847-2853.
72. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. (2001) Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104, 746-749.
73. Rennick DM, Fort MM. (2000) Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G829-833.
74. Li MC, He SH. (2004) IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J. Gastroenterol. 10, 620-625.
75. Tilg H, Ulmer H, Kaser A, Weiss G. (2002) Role of IL-10 for induction of anemia during inflammation. J. Immunol. 169, 2204-2209.
76. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, et al. (2002) Treatment of Crohns disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 50, 191-195.
77. Paul WE. (1991) Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 77, 1859-1870.
78. George J, Mulkins M, Shaish A, Casey S, Schatzman R, Sigal E, et al. (2000) Interleukin (IL)-4 deficiency does not influence fatty streak formation in C57BL/6 mice. Atherosclerosis 153, 403-411.
79. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP. (2001) T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 103, 2610-2616.
80. Khew-Goodall Y, Wadham C, Stein BN, Gamble JR, Vadas MA. (1999) Stat6 activation is essential for interleukin-4 induction of P-selectin transcription in human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19, 1421-1429.
81. Cornicelli JA, Butteiger D, Rateri DL, Welch K, Daugherty A. (2000) Interleukin-4 augments acetylated LDL-induced cholesterol esterification in macrophages. J. Lipid Res. 41, 376-383.
82. Vessillier S, Adams G, Montero-Melendez T, Jones R, Seed M, Perretti M, Chernajovsky Y. (2012) Molecular engineering of short half-life small peptides (VIP, alpha-MSH and gamma3-MSH) fused to latency-associated peptides results in improved anti-inflammatory therapeutics. Ann Rheum Dis 17, 143-149.
83. Fingleton B. (2006) Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci. 11, 479-491.
84. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. (2006) Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp. Biol. Med. (Maywood) 231, 20-27.
85. Amalinei C, Caruntu ID, Giusca SE, Balan RA. (2010) Matrix metalloproteinases involvement in pathologic conditions. Rom. J. Morphol. Embryol. 51, 215-228.
86. Piper PJ, Said SI, Vane JR. (1970) Effects on smooth muscle preparations of unidentified vasoactive peptides from intestine and lung. Nature 225, 1144-1146.
87. Said SI, Mutt V. (1970) Polypeptide with broad biological activity: isolation from small intestine. Science 169, 1217-1218.
88. Ganea D, Delgado M. (2002) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit. Rev. Oral Biol. Med. 13, 229-237.
89. Henning RJ, Sawmiller DR. (2001) Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc. Res. 49, 27-37.
90. Lipton JM, Ceriani G, Macaluso A, McCoy D, Carnes K, Biltz J, et al. (1994) Antiinflammatory effects of the neuropeptide alpha-MSH in acute, chronic, and systemic inflammation. Ann. N. Y. Acad. Sci. 741, 137-148.
91. Stack MS, Gray RD. (1989) Comparison of vertebrate collagenase and gelatinase using a new fluorogenic substrate peptide. J. Biol. Chem. 264, 4277-4281.
92. Ye QZ, Johnson LL, Yu AE, Hupe D. (1995) Reconstructed 19 kDa catalytic domain of gelatinase A is an active proteinase. Biochemistry 34, 4702-4708.
93. Peng KW, Morling FJ, Cosset FL, Murphy G, Russell SJ. (1997) A gene delivery system activatable by diseaseassociated matrix metalloproteinases. Hum. Gene. Ther. 8, 729-738.
94. Vessillier S, Adams G, Chernajovsky Y. (2004) Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3. Protein Eng. Des. Sel. 17, 829-835.
95. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, et al. (1999) Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 284, 1664-1666.
96. Sandy JD, Verscharen C. (2001) Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem. J. 358, 615-626.
97. Fosang AJ, Rogerson FM, East CJ, Stanton H. (2008) ADAMTS-5: the story so far. Eur. Cell Mater. 15, 11-26.
98. Sandy JD. (2006) A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cartilage 14, 95-100.
99. Hills R, Mazzarella R, Fok K, Liu M, Nemirovskiy O, Leone J, et al. (2007) Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate. J. Biol. Chem. 282, 11101-11109.
100. Gentry LE, Nash BW. (1990) The pro domain of pre-protransforming growth factor beta 1 when independently expressed is a functional binding protein for the mature growth factor. Biochemistry 29, 6851-6857.
101. Bottinger EP, Factor VM, Tsang ML, Weatherbee JA, Kopp JB, Qian SW, et al. (1996) The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc. Natl. Acad. Sci. U S A 93, 5877-5882.
102. Vodovotz Y, Chesler L, Chong H, Kim SJ, Simpson JT, DeGraff W, et al. (1999) Regulation of transforming growth factor beta1 by nitric oxide. Cancer Res. 59, 2142-2149.
103. McMahon GA, Dignam JD, Gentry LE. (1996) Structural characterization of the latent complex between transforming growth factor beta 1 and beta 1-latency-associated peptide. Biochem. J. 313, 343-351.
104. Ali NA, Gaughan AA, Orosz CG, Baran CP, McMaken S, Wang Y, et al. (2008) Latency associated peptide has in vitro and in vivo immune effects independent of TGF-beta1. PLoS One 3, e1914.
105. Holle L, Song W, Holle E, Wei Y, Li J, Wagner TE, et al. (2009) In vitro-and in vivo-targeted tumor lysis by an MMP2 cleavable melittin-LAP fusion protein. Int. J. Oncol. 35, 829-835.
106. Holle L, Song W, Holle E, Wei Y, Wagner T, Yu X. (2003) A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo. Int. J. Oncol. 22, 93-98.
107. Leuschner C, Hansel W. (2004) Membrane disrupting lytic peptides for cancer treatments. Curr. Pharm. Des. 10, 2299-2310.